Redemplo
What Redemplo is used for
Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Redemplo
- Active substance
- plozasiran
- Disease area
- Hyperlipoproteinemia Type I
- Medicine group
- Lipid modifying agents
- ATC code
- C10AX
- Marketing authorisation holder
- Arrowhead Pharmaceuticals Ireland Limited
- Authorised in the EU since
- 2026
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Redemplo used for?
Redemplo is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with familial chylomicronaemia syndrome (FCS) (see section 4.2 for patient selection criteria).
What is the active substance in Redemplo?
Redemplo contains plozasiran.
Who makes Redemplo?
The EU marketing authorisation holder is Arrowhead Pharmaceuticals Ireland Limited.
Is Redemplo an orphan medicine?
Yes. Redemplo is designated an orphan medicine in the EU, for a rare disease (Hyperlipoproteinemia Type I).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU